^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:BRY812 (Microtubule inhibitor, LIV-1-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res
    Title:

    Abstract B075: Anti-human LIV-1 antibody drug conjugate for treatment of metastatic prostate cancer

    Published date:
    06/02/2023
    Excerpt:
    In vitro and in vivo studies demonstrated the antitumor activity of BRY812 for the treatment of prostate and ER+ and triple-negative breast cancers with a better safety profile and a larger therapeutic window.
    DOI:
    https://doi.org/10.1158/1538-7445.PRCA2023-B075